« Return to News | Clinical Intelligence

Soligenix completes phase I in SGX203 for pediatric Crohn’s

Wednesday, July 3, 2013 08:50 AM

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, has enrolled and treated all patients in the phase I study BDP-PCD-01, a clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease. The SGX203 development program previously has received Fast Track and Orphan Drug designations from the FDA.

The objective of the study was to further characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of the company's proprietary oral BDP formulation. The study in healthy male and female adolescents and young adults provided complementary data to that previously obtained and confirmed the safety profile observed in all previous clinical studies with oral BDP.

This study enrolled 24 subjects between the ages of 18 to 22, with all assessments completed in May. Preliminary results indicate that the PK profile in this population is consistent with the profile established in previous studies in a broader population and supports a twice-daily dosing regimen. SGX203 administration (6mg BDP twice daily over seven days) was found to be safe and well-tolerated.

“The refined model will provide the justification for limited PK sampling in the subsequent phase II/III pediatric clinical study and will help inform the dose selection for the phase III component of the study,” said Kevin J. Horgan, M.D., senior vice president and chief medical officer of Soligenix.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.